Skip to main content

Advertisement

SpringerLink
Log in

Role of Neoadjuvant Chemotherapy (NACT) Followed by Surgical Cytoreduction in Advanced Epithelial Ovarian Cancer

  • Original Article
  • Published:
The Journal of Obstetrics and Gynecology of India Aims and scope Submit manuscript

Abstract

Objectives

To study the role of neoadjuvant chemotherapy (NACT) followed by surgical cytoreduction in the management of advanced epithelial ovarian cancers.

Methods

A prospective hospital based study of patients with advanced epithelial ovarian cancers (stage III and IV) was conducted at Gujarat Cancer & Research Institute, Ahmedabad during August 2008 to August 2010. Total 50 patients were treated with NACT followed by surgical cytoreduction and followed up till August 2010. Response to NACT, optimal cytoreduction rate and overall response rate were analyzed.

Results

There were 43 patients (86%) with stage III disease and 7 (14%) with stage IV disease. All patients were given NACT and after NACT, complete response occurred in 17 patients (34%), 27 (54%) had partial response. Optimal surgical cytoreduction could be achieved in 36(72%) of the patients. The median follow up was 19 months.

Conclusions

NACT followed by surgical cytoreduction is a promising treatment strategy for the management of advanced epithelial ovarian cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yeole BB, Kumar AV, Kurkure A, et al. Population-based survival from cancers of breast, cervix and ovary in women in Mumbai, India. Asian Pac J Cancer Prev. 2004;5:308–15.

    PubMed  Google Scholar 

  2. Bray F, Loos AH, Tognazzo S, et al. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953–2000. Int J Cancer. 2005;113:977–90.

    Article  PubMed  CAS  Google Scholar 

  3. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin. 2001;15:15–36.

    Article  Google Scholar 

  4. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26.

    Article  PubMed  Google Scholar 

  5. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Lippincott: Williams and Wilkins; 2001. p. 1597–632.

    Google Scholar 

  6. Beard CM, Hartmann LC, Atkinson EJ, et al. The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935–1991. Ann Epidemiol. 2000;10:14–23.

    Article  PubMed  CAS  Google Scholar 

  7. van der Burg ME. Advanced ovarian cancer. Curr Treat Options Oncol. 2001;2(2):109–18.

    Article  PubMed  Google Scholar 

  8. Mazzeo F, Berliere M, Kerger J, et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol. 2003;90:163–9.

    Article  PubMed  CAS  Google Scholar 

  9. Le T, Faught W, Hopkins L, et al. Primary chemotherapy and adjuvant tumor debulking in the management of advanced stage epithelial ovarian cancers. Int J Gynecol Cancer. 2005;15(5):770–5.

    Article  PubMed  CAS  Google Scholar 

  10. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.

    Article  PubMed  Google Scholar 

  11. Patel S, Desai A, Chauhan A, et al. Single agent carboplatin as neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Indian J Gynecol Oncol. 2009;9(1):51–6.

    Google Scholar 

  12. Hou JY, Kelly MG, Yu H, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol. 2007;105(1):211–7.

    Article  PubMed  CAS  Google Scholar 

  13. Chan YM, Ng TY, Ngan HYS, et al. Quality of life in women treated with NACT for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol. 2003;88:9–16.

    Article  PubMed  CAS  Google Scholar 

  14. Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. A French multicenter study. Cancer. 2001;91:2329–34.

    Article  PubMed  CAS  Google Scholar 

  15. Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in FIGO stage IIIc ovarian carcinoma. Cancer. 2001;92:2585–91.

    Article  PubMed  CAS  Google Scholar 

  16. Le T, Williams K, Senterman M, et al. Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with NACT & delayed primary surgical debulking. Gynecol Oncol. 2007;106:160–3.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics & Gynecology, Gujarat Cancer Research Institute, Ahmedabad, 380 016, India

    Sonia Batra (Resident) & Kalpna S. Dave (Professor & Head)

  2. Department of Community Medicine, AMC MET Medical College, Ahmedabad, 380008, India

    Himanshu Nayak (Assistant Professor)

  3. 244, APR Colony, Katanga, Jabalpur, 482001, Madhya Pradesh, India

    Sonia Batra (Resident)

Authors
  1. Sonia Batra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Himanshu Nayak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kalpna S. Dave
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonia Batra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Batra, S., Nayak, H. & Dave, K.S. Role of Neoadjuvant Chemotherapy (NACT) Followed by Surgical Cytoreduction in Advanced Epithelial Ovarian Cancer. J Obstet Gynecol India 62, 541–545 (2012). https://doi.org/10.1007/s13224-011-0106-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13224-011-0106-8

Keywords

Search

Navigation